1. Home
  2. TARS vs SAM Comparison

TARS vs SAM Comparison

Compare TARS & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TARS
  • SAM
  • Stock Information
  • Founded
  • TARS 2016
  • SAM 1984
  • Country
  • TARS United States
  • SAM United States
  • Employees
  • TARS N/A
  • SAM N/A
  • Industry
  • TARS Medicinal Chemicals and Botanical Products
  • SAM Beverages (Production/Distribution)
  • Sector
  • TARS Health Care
  • SAM Consumer Staples
  • Exchange
  • TARS Nasdaq
  • SAM Nasdaq
  • Market Cap
  • TARS 2.8B
  • SAM 2.4B
  • IPO Year
  • TARS 2020
  • SAM 1995
  • Fundamental
  • Price
  • TARS $67.56
  • SAM $222.73
  • Analyst Decision
  • TARS Strong Buy
  • SAM Hold
  • Analyst Count
  • TARS 7
  • SAM 10
  • Target Price
  • TARS $69.43
  • SAM $247.89
  • AVG Volume (30 Days)
  • TARS 613.1K
  • SAM 207.7K
  • Earning Date
  • TARS 11-04-2025
  • SAM 10-23-2025
  • Dividend Yield
  • TARS N/A
  • SAM N/A
  • EPS Growth
  • TARS N/A
  • SAM 23.02
  • EPS
  • TARS N/A
  • SAM 8.25
  • Revenue
  • TARS $295,521,000.00
  • SAM $1,981,609,000.00
  • Revenue This Year
  • TARS $139.46
  • SAM N/A
  • Revenue Next Year
  • TARS $49.91
  • SAM $1.00
  • P/E Ratio
  • TARS N/A
  • SAM $27.00
  • Revenue Growth
  • TARS 254.45
  • SAM N/A
  • 52 Week Low
  • TARS $38.51
  • SAM $185.34
  • 52 Week High
  • TARS $76.81
  • SAM $329.55
  • Technical
  • Relative Strength Index (RSI)
  • TARS 54.32
  • SAM 51.09
  • Support Level
  • TARS $65.30
  • SAM $214.88
  • Resistance Level
  • TARS $74.83
  • SAM $243.73
  • Average True Range (ATR)
  • TARS 2.87
  • SAM 8.10
  • MACD
  • TARS -0.99
  • SAM 0.37
  • Stochastic Oscillator
  • TARS 19.64
  • SAM 29.36

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

Share on Social Networks: